摘要
目的探讨羟氯喹联合复方倍他米松治疗口腔扁平苔藓的有效性与安全性。方法选取2015年11月—2016年11月在邯郸市口腔医院治疗的口腔扁平苔藓患者125例,根据用药方案不同分成对照组(62例)和治疗组(63例)。对照组患者于病变黏膜处多点注射复方倍他米松注射液,1 mL加入2%利多卡因1 mL,1次/周;治疗组患者在对照组的基础上口服硫酸羟氯喹片,2片/次,2次/d。两组患者均经过6个月治疗。观察两组患者临床疗效,比较治疗前后两组患者IL-17、γ-干扰素(IFN-γ)和IL-4水平以及视觉模拟(VAS)评分。结果治疗后,对照组临床总有效率为83.87%,显著低于治疗组的96.83%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组复发率为22.58%,显著高于治疗组的7.94%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清IL-17、IL-4水平均显著降低,血清IFN-γ水平显著升高,同组比较差异具有统计学意义(P<0.05);且治疗组IL-17、IFN-γ和IL-4水平明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者VAS评分均显著降低(P<0.05);且治疗组降低更明显,两组比较差异具有统计学意义(P<0.05)。结论硫酸羟氯喹联合复方倍他米松治疗口腔扁平苔藓疗效较好,复发率低,安全性高,具有一定的临床推广应用价值。
Objective To investigate the efficacy and safety of hydroxychloroquine combined with Compound Betamethasone Injection in treatment of oral lichen planus. Methods Patients（125 cases） with oral lichen planus in Handan Stomatological Hospital from November 2015 to November 2016 were divided into control（62 cases） and treatment（63 cases） groups based on different treatments. Patients in the control group were multipoint injection administered with Compound Betamethasone Injection at the lesion＇s mucosa, 1 mL added into 2% lidocaine 1 mL, once weekly. Patients in the treatment group were po administered with Hydroxychloroquine Sulfate Tablets on the basis of the control group, 2 tablets/time, twice daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the IL-17, IFN-γ and IL-4 level, and VAS scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 83.87%, which was significantly lower than 96.83% in the treatment group, and there were differences between two groups（P〈0.05）. After treatment, the recurrence rate in the control group was 22.58%, which was significantly higher than 7.94% in the treatment group, and there were differences between two groups（P〈0.05）. After treatment, IL-17 and IL-4 levels in two groups were significantly decreased, but IFN-γ levels were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. And IL-17, IFN-γ and IL-4 levels in the treatment group was significantly better than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the VAS scores in two groups were significantly decreased（P〈0.05）. And the VAS scores in the treatment group were significantly lower than that in the control group（P〈0.05）. Conclusion Hydroxychloroquine combined with Compound Betamethasone Injection has good efficacy in treatment of oral lichen planus with low recurrence rate and high safety, which has a certain clinical application value.
出处
《现代药物与临床》
CAS
2018年第1期110-113,共4页
Drugs & Clinic
基金
邯郸市科学技术局项目(1528108079-4)
